Skip to content
21+ onlyResearch-grade peptidesExternal reports listed where availableDelivery £20Free delivery on orders of £300 or more10% off merchandise with crypto
Hormone & Growth5 min readPublished 16 August 2026Reviewed 16 August 2026

CJC-1295 and Ipamorelin: two routes into growth-axis research

A comparison of GHRH-analogue and growth-hormone-secretagogue research pathways.

Apex Pharma Research

CJC-1295 belongs to the family of synthetic growth-hormone-releasing-hormone analogues. Ipamorelin was characterised as a selective growth-hormone secretagogue in experimental systems. They engage the growth axis through different receptor mechanisms.

The distinction matters when interpreting a protocol: analogue structure, duration of observation and assay context can change the question being tested. A product label is not a substitute for the methods section of a cited study.

Apex catalogue records distinguish CJC-1295 No DAC products from other identities and list presentation and dosage separately. No listing implies an approved clinical use.

References

  1. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 ↗
  2. Ipamorelin, the first selective growth hormone secretagogue ↗

Research use only. All products described on this site are for laboratory research purposes. They are not medicines and are not intended to diagnose, treat, cure or prevent any disease.